GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Almirall SA (XMAD:ALM) » Definitions » EPS (Diluted)

Almirall (XMAD:ALM) EPS (Diluted) : €-0.07 (TTM As of Jun. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Almirall EPS (Diluted)?

Almirall's Earnings per Share (Diluted) for the three months ended in Jun. 2023 was €0.02. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.07.

Almirall's EPS (Basic) for the three months ended in Jun. 2023 was €0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.07.

Almirall's EPS without NRI for the three months ended in Jun. 2023 was €0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2023 was €0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Almirall EPS (Diluted) Historical Data

The historical data trend for Almirall's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Almirall EPS (Diluted) Chart

Almirall Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 0.42 -0.23 0.02 -0.20

Almirall Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 -0.13 0.04 0.02 -

Competitive Comparison of Almirall's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Almirall's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Almirall's PE Ratio distribution charts can be found below:

* The bar in red indicates where Almirall's PE Ratio falls into.



Almirall EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Almirall's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-38.474-0)/196.992
=-0.20

Almirall's Diluted EPS for the quarter that ended in Jun. 2023 is calculated as

Diluted EPS (Q: Jun. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(4.315-0)/209.216
=0.02

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Almirall  (XMAD:ALM) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Almirall EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Almirall's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Almirall (XMAD:ALM) Business Description

Traded in Other Exchanges
Address
Ronda General Mitre 151, Barcelona, ESP, 08022
Almirall SA is a Spain-based company engaged in development, manufacture, and selling pharmaceutical products across a range of therapeutic areas. It aims to provide treatments in areas of dermatology, respiratory, gastrointestinal, central nervous systems, and other specialties. The company operates in five segments: Sales of its own network, sales of licensees, Research and developments, Sales of Therapeutic dermatological products in the U.S., and Corporate management. The medical dermatology business in the Europe is the key driver of the company's operation. Other than Europe, the company also operates in the Americas, Asia, Africa, and Oceania through subsidiaries.

Almirall (XMAD:ALM) Headlines

From GuruFocus

ALFI Inc: A Little Known Yet Compelling Ad-Tech Play

By Ishan Majumdar Ishan Majumdar 05-07-2021

Alfi: Solid Growth Potential Lies Ahead

By Ishan Majumdar Ishan Majumdar 06-02-2021